The primary objective of the study is to evaluate the safety and feasibility of treating patients with a history of iTTP with efgartigimod, an FcRn inhibitor that reduces IgG autoantibodies, including those responsible for ADAMTS13 depletion.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Raj Kasthuri
Medicine-Hematology
Clinical or Medical
Interventional
Rare Diseases
25-0495
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
